ICON CEO Ciaran Murray Elected Chairman of Association of Clinical Research Organisations


Dublin, Ireland, 14 January, 2014 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that its Chief Executive, Ciaran Murray, has been elected 2014 Chairman of the Association of Clinical Research Organisations (ACRO).  ICON Legal Counsel, Diarmaid Cunningham, has also been elected as Secretary of ACRO for a second term. 
 
Since its foundation in 2002, ACRO has been committed to strengthening public understanding and confidence in clinical research and to highlighting CRO expertise in all aspects of the clinical research enterprise. ACRO represents the CRO industry globally to pharmaceutical, biotech and medical device companies, regulators and legislators, peer associations, academic organisations, patient groups, the media and the public. 
 
“I am honoured to lead ACRO at this time when clinical research organizations are increasingly being recognized for the innovation and expertise we bring to the drug development process,” said Mr. Murray. “I look forward to continuing the work that ACRO has done in promoting our industry as one that conducts safe, ethical and high-quality clinical research to deliver medicines that benefit patients worldwide.”
 
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics and medical devices. The association provides an active voice for the CRO industry globally. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ approximately 100,000 professionals worldwide and annually conduct more than 11,000 clinical trials involving nearly two million participants in 115 countries. For more information, please visit www.acrohealth.org. 
 
 
ICON Media Contact
Genevieve Tuck
Weber Shandwick
Tel: +44 (0)20 7067 0655 
gtuck@webershandwick.com
 
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions.  These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release.  The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.